Sanjukta Das
Sanjukta Das
Assistant Professor
Dr. Sanjukta has 12 years of experience in bioinformatics and data analysis. She uses integrative computational and statistical methods to analyze genomics and transcriptomics data in order to understand the underlying mechanism of transcription and molecular pathways in tumors. Her current lab is actively working on understanding the altered transcriptional program that evade immune system in cancer and detecting targetable biomarkers by integrating high throughput gene expression data and DNA chromatin-binding at the single cell and bulk tumor levels.
Profile Links
Email :
[email protected]
Scopus Id :
57222029676
Google Scholar :
https://scholar.google.com/citations?hl=en&user=XDuoExMAAAAJ
Social Links
Educational Qualification
Administrative Responsibility
Co-Ordinator
Awards & Honours
University Gold Medal In Bioscience, University of Fakir Mohan
- Visiting Scientist, Dana Farber Cancer Institute and Harvard Medical School (2022-present), USA
- PhD, Indian Institute of Sciences, Bangalore, Karnataka, India (2018)
- Postdoctoral Fellowship, Dana Farber Cancer Institute and Harvard Medical School (2018-2022)
- M.Sc., Fakir Mohan university, Balasore, Odisha, India
Administrative Responsibility
Co-Ordinator
Awards & Honours
University Gold Medal In Bioscience, University of Fakir Mohan
Journals/Conferences :
Genome-wide targets regulated by OsMADS1 in rice florets reveal its DNA recognition properties. Imtiyaz Khanday*, Sanjukta Das*, Grace Chongloi*, Manju Bansal, Ueli Grossniklaus and Usha Vijayraghavan (2016); Plant Physiology, 172(1), 372-388.
*Contributed equally
Variation of gene expression in plants is influenced by gene architecture and structural properties of promoters. its DNA recognition properties. Sanjukta Das and Manju Bansal (2019); PLOS One, 14(3):e0212678.
Synergistic Anti-Tumor Effect of Combining Selective CDK7 and BRD4 Inhibition in Neuroblastoma. Gao, Yang, Marina Volegova, Nicole Nasholm, Sanjukta Das, Nicholas Kwiatkowski, Brian J. Abraham, Tinghu Zhang et al. (2021); Frontiers in oncology, 11:773186-773186.
Mesenchymal and adrenergic cell lineage states in neuroblastoma possess distinct immunogenic phenotypes. Sengupta S*, Das S*, Crespo AC, Cornel AM, Patel AG, Mahadevan NR, Campisi M, Ali AK, Sharma B, Rowe JH, Huang H., Rani E. George (2022); Nature Cancer, 2022 Sep 22:1-9.
*Contributed equally
Epigenetic modulation of neuroblastoma enhances T- and NK-cell immunogenicity by inducing a tumor cell lineage switch. Cornel A.M, Dunnebach E. Hofman D.A, Sanjukta Das, Sengupta S, van den Ham F, Wienke J., Strijker J.G.M., van den Beemt D.A.M.H., Essing A.H.W. , Koopmans B, Engels S.A.G , Lo Presti V., Szanto C.S, George R.E, Molenaar J.J., van Heesch S., Dierselhuis M.P, Nierkens S. (2022); Journal of ImmunoTherapy of Cancer, 10(12).
Genome-wide targets regulated by OsMADS1 in rice florets reveal its DNA recognition properties. Imtiyaz Khanday*, Sanjukta Das*, Grace Chongloi*, Manju Bansal, Ueli Grossniklaus and Usha Vijayraghavan (2016); Plant Physiology, 172(1), 372-388.
*Contributed equally
Variation of gene expression in plants is influenced by gene architecture and structural properties of promoters. its DNA recognition properties. Sanjukta Das and Manju Bansal (2019); PLOS One, 14(3):e0212678.
Synergistic Anti-Tumor Effect of Combining Selective CDK7 and BRD4 Inhibition in Neuroblastoma. Gao, Yang, Marina Volegova, Nicole Nasholm, Sanjukta Das, Nicholas Kwiatkowski, Brian J. Abraham, Tinghu Zhang et al. (2021); Frontiers in oncology, 11:773186-773186.
Mesenchymal and adrenergic cell lineage states in neuroblastoma possess distinct immunogenic phenotypes. Sengupta S*, Das S*, Crespo AC, Cornel AM, Patel AG, Mahadevan NR, Campisi M, Ali AK, Sharma B, Rowe JH, Huang H., Rani E. George (2022); Nature Cancer, 2022 Sep 22:1-9.
*Contributed equally
Epigenetic modulation of neuroblastoma enhances T- and NK-cell immunogenicity by inducing a tumor cell lineage switch. Cornel A.M, Dunnebach E. Hofman D.A, Sanjukta Das, Sengupta S, van den Ham F, Wienke J., Strijker J.G.M., van den Beemt D.A.M.H., Essing A.H.W. , Koopmans B, Engels S.A.G , Lo Presti V., Szanto C.S, George R.E, Molenaar J.J., van Heesch S., Dierselhuis M.P, Nierkens S. (2022); Journal of ImmunoTherapy of Cancer, 10(12).